Published in
American Society of Hematology, Blood, Supplement 1(140), p. 10148-10149, 2022
DOI: 10.1182/blood-2022-160173
Links
Tools
MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
Journal article published in 2022 by
Amrita Y. Krishnan,
Salomon Manier,
Evangelos Terpos,
Saad Usmani,
Josephine Khan,
Rachel Pearson 
,
Suzette Girgis,
Yue Guo,
Dana McAleer,
Yunsi Olyslager,
Tobias Kampfenkel,
Niels W. C. J. van de Donk
,
Suzette Girgis,
Yue Guo,
Dana McAleer,
Yunsi Olyslager,
Tobias Kampfenkel,
Niels W. C. J. van de Donk
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 